Insulet Corporation10.29.19
Insulet Corporation, an expert in tubeless insulin pump technology with its Omnipod Insulin Management System, has been granted FDA clearance for the use of Fiasp (fast-acting insulin aspart) with the Omnipod Insulin Management System and the Omnipod DASH Insulin Management System for adults. Fiasp is a new ultra-fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster than Novo Nordisk’s NovoLog, so it more closely matches a body’s typical insulin response to a meal, thereby improving glycemic control. As a result, Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
Insulet completed extensive testing with the support of Novo Nordisk to demonstrate that Fiasp is safe and can be used with both the Omnipod System, as well as the Omnipod DASH Insulin Management System. Insulet is the first insulin pump in the United States to obtain this indication. The Omnipod Insulin Management System has been indicated for use with Fiasp in Europe since October 2018.
“Omnipod can now be used with the full spectrum of insulin, from generic to branded to ultra-fast-acting, and we are thrilled to deliver this additional flexibility for people to use their insulin of choice with the Omnipod System,” said Dr. Trang Ly, senior vice president, medical director. “Expanding our labeling to include Fiasp also opens the door for existing Fiasp users to seamlessly transition to an Omnipod System for their insulin delivery needs and further demonstrates our commitment to innovation.”
Insulet completed extensive testing with the support of Novo Nordisk to demonstrate that Fiasp is safe and can be used with both the Omnipod System, as well as the Omnipod DASH Insulin Management System. Insulet is the first insulin pump in the United States to obtain this indication. The Omnipod Insulin Management System has been indicated for use with Fiasp in Europe since October 2018.
“Omnipod can now be used with the full spectrum of insulin, from generic to branded to ultra-fast-acting, and we are thrilled to deliver this additional flexibility for people to use their insulin of choice with the Omnipod System,” said Dr. Trang Ly, senior vice president, medical director. “Expanding our labeling to include Fiasp also opens the door for existing Fiasp users to seamlessly transition to an Omnipod System for their insulin delivery needs and further demonstrates our commitment to innovation.”
